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The Coronavirus (COVID-19), (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)) has been spreading since its identification in cluster of cases of pneumonia in Wuhan, Hubei Province, China. The symptoms of the infected patients have wide range from asymptommatic or common cold symptoms to pneumonia symptoms. The prognosis may vary from full recovery to the severe acute respiratory distress syndrom and death. So far, many different treatment modalities have been tried and offered by different groups of physicians. Nowadays, many studies are on progress to develop vaccine for prevention, and to develop drugs for medical treatment. There are a few studies about the effect of interferon therapy in COVID-19 patients ([@bib0004]; [@bib0005]; [@bib0002]). Effect of type 1 interferon (such as IFN-α and IFN-β) therapy as a potential treatment against coronavirus (COVID-19, MERS and SARS) was shown in many studies and researches are maintaining, more comprehensive data will be available soon ([@bib0004]; [@bib0005]; [@bib0002]). A recently published study has supported that type 1 interferons can be used as a potential therapy against COVID-19 ([@bib0004]). It is noted in this research that interferon therapy can be effective against SARS-CoV, and SARS-CoV-2 may be more sensitive to interferon than other coronaviruses and necessity for the use of interferons in early stage of treatment ([@bib0004]). As to be parallel with this treatment suggestion and researches, we wanted to present our 31 years old male patient with Multiple Sclerosis (MS) who was under beta interferon treatment since he got the diagnosis approximately for 2 years. At the medical history of the patient there is only seasonal allergic rhinitis and MS. Before the onset of the symptoms he has a history of contact with COVID-19 positive patients who were his co-workers. After 1week of exposure he was admitted to the emergency room (ER) with dry cough and shortness of breath complaints.

There was no drug use other than interferon which he had been using for 2 years. He had no fever. His respiratory rate and oxygen saturation were normal. In physical examination, respiratory sounds were normal, White blood cells (WBC), hemoglobin (HGB), platelet count (PLT), C-reactive protein level, liver function tests, kidney function tests, D-Dimer level were normal. COVID PCR test obtained from oropharyngeal and nasopharyngeal swab was positive. There were subpleural located ground glass opacities in lower regions at right lung in chest computed tomography ([Fig. 1](#fig0001){ref-type="fig"} ). Hydroxychloroquine, azithromycin and enoxaparin sodium treatment were initiated as an addition his interferon therapy. In his follow up, he didn\'t develop other symptoms except cough. Therapy maintained 5 days. All laboratory tests that performed in fifth day were normal. Our patient who did not have any other complaints has been using interferon therapy for 2 years. Not only length of hospital stays of our patient who was hospitalized with diagnosis of COVID-19 pneumonia was short but also his symptoms remained markedly faint. Hydroxychloroquine and azithromycin were given our patient combined with interferon during time of hospital stay. In his follow up, our patient\'s clinical features were better and our patient was discharged in the seventh day of his admission.Fig. 1Subpleural located ground glass opacities in lower regions at right lung in chest computed tomography, comprehensive to the first chest CT ground glass opacity of the lesion is suitable with regression.Fig. 1

IFNs play a crucial role in the immune response to viral infections. Type 1 interferon binds to ubiquitously expressed co-receptors on the cell surface ([@bib0003]). Jak stat signaling pathway activation and also the upregulation of numerous genes stimulated by IFN begin after this binding ([@bib0003]). IFN stimulated genes encode many proteins that mediate antiviral activities. This case made us consider that interferon therapy might have favorable effect on severity of symptoms and length of hospital stay of patients with COVID-19. IFN-I treatment may be an efficient and safe against SARS-CoV-2 and this should be kept in mind. However, as this individual was treated with other anti-viral agents, it is not possible to definitively link the short hospital stay to treatment. However, that the patient was relatively young and exhibited good prognostic features such as lack of D-dimer, lymphopenia ([@bib0001]) could suggest that prophylactic interferon may aid recovery. Further studies of the experiences of people with MS who take type I interferons, such as beta interferons who get COVID 19 ([@bib0006]), may clarify this further.
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